MCID: ALC004
MIFTS: 63

Alcohol Abuse

Categories: Rare diseases, Genetic diseases, Mental diseases

Aliases & Classifications for Alcohol Abuse

MalaCards integrated aliases for Alcohol Abuse:

Name: Alcohol Abuse 37 12 51 14 69
Alcohol-Related Disorders 41 69
Alcoholic Intoxication, Chronic 69
Ethanol Abuse 12
Alcoholism 41

Classifications:



External Ids:

Disease Ontology 12 DOID:1574
ICD10 32 F10.1
ICD9CM 34 305.0 305.00
NCIt 46 C20701
SNOMED-CT 64 15167005 304606004

Summaries for Alcohol Abuse

Disease Ontology : 12 A substance abuse that involves the recurring use of alcoholic beverages despite negative consequences.

MalaCards based summary : Alcohol Abuse, also known as alcohol-related disorders, is related to viral hepatitis and alcohol use disorder, and has symptoms including hangover from alcohol and hangover from any alcohol or other drugs substance. An important gene associated with Alcohol Abuse is CYP2E1 (Cytochrome P450 Family 2 Subfamily E Member 1), and among its related pathways/superpathways are Porphyrin and chlorophyll metabolism and Circadian rythm related genes. The drugs Bupropion and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include brain, liver and testes, and related phenotypes are Decreased shRNA abundance and Decreased shRNA abundance

Wikipedia : 72 Alcohol abuse is a previous psychiatric diagnosis in which there is recurring harmful use of alcohol... more...

Related Diseases for Alcohol Abuse

Diseases in the Alcohol Abuse family:

Alcohol Sensitivity, Acute Alcohol Use Disorder

Diseases related to Alcohol Abuse via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 193)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 30.3 ABCB7 GGT1 GPT SLC17A5
2 alcohol use disorder 30.2 ALDH2 DRD2 SLC6A4
3 liver disease 30.1 ABCB7 CYP2E1 GGT1 GPT SLC17A5 TF
4 alcoholic hepatitis 29.9 CYP2E1 GPT SLC17A5
5 conduct disorder 29.9 ALDH2 DRD2 DRD4 SLC6A4
6 alcoholic liver cirrhosis 29.9 ALDH2 CYP2E1 SLC17A5 TF
7 pathological gambling 29.8 DRD2 DRD3 DRD4 SLC6A4
8 mood disorder 29.8 BDNF DRD2 DRD4 SLC6A4
9 delusional disorder 29.7 DRD2 DRD3 DRD4
10 cocaine dependence 29.7 DRD2 DRD3 SLC6A4
11 gilles de la tourette syndrome 29.7 BDNF DRD2 DRD4
12 eating disorder 29.6 BDNF CNR1 DRD2 SLC6A4
13 liver cirrhosis 29.6 ALDH2 CYP2E1 GGT1 GPT SLC17A5 TF
14 anxiety 29.5 BDNF CNR1 SLC6A4
15 cocaine abuse 29.5 DRD2 PRL SLC6A4
16 bulimia nervosa 2 29.4 BDNF PRL SLC6A4
17 alexithymia 29.3 ANKK1 DRD2 SLC6A4
18 personality disorder 29.2 ALDH2 BDNF DRD2 DRD3 DRD4 SLC6A4
19 body mass index quantitative trait locus 11 29.1 CNR1 CYP2E1 DRD2 FAAH GGT1 GPT
20 antisocial personality disorder 29.0 ALDH2 ANKK1 DRD2 SLC6A4
21 schizophrenia 28.6 BDNF CNR1 DRD2 DRD3 DRD4 PRL
22 psychotic disorder 28.5 BDNF DRD2 DRD3 DRD4 PRL SLC6A4
23 bipolar disorder 28.5 BDNF DRD2 DRD3 DRD4 GGT1 PRL
24 disease of mental health 28.3 ALDH2 BDNF CNR1 DRD2 DRD3 DRD4
25 substance abuse 28.1 BDNF DRD2 DRD3 DRD4 GABRA2 PRL
26 alcohol dependence 27.7 AKR1A1 ALDH2 ALDH9A1 ANKK1 BDNF CNR1
27 fetal alcohol syndrome 12.5
28 wernicke-korsakoff syndrome 11.3
29 cerebellar degeneration 11.1
30 hyperlipoproteinemia, type v 11.0
31 lipomatosis, multiple symmetric 11.0
32 dystonia 11, myoclonic 11.0
33 nuchal bleb, familial 11.0
34 osteonecrosis 11.0
35 beriberi 11.0
36 megalocytic interstitial nephritis 11.0
37 nonalcoholic steatohepatitis 11.0
38 atrial fibrillation and stroke 11.0
39 cerebral beriberi 11.0
40 hypersomnia 11.0
41 korsakoff's amnesic syndrome 11.0
42 tremor 11.0
43 paraquat poisoning 10.5 GPT SLC17A5
44 pyridoxine deficiency 10.5 GPT SLC17A5
45 kwashiorkor 10.4 GPT SLC17A5 TF
46 analbuminemia 10.4 GPT SLC17A5 TF
47 obstructive jaundice 10.4 GGT1 GPT SLC17A5
48 methanol poisoning 10.4 AKR1A1 CYP2E1
49 alcohol-induced mental disorder 10.4 DRD2 SLC6A4
50 wilson disease 10.4 DRD2 GPT TF

Comorbidity relations with Alcohol Abuse via Phenotypic Disease Network (PDN): (show all 20)


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Alcohol-Induced Mental Disorder
Alcoholic Cardiomyopathy Alcoholic Gastritis
Alcoholic Hepatitis Alcoholic Liver Cirrhosis
Alcoholic Neuropathy Cocaine Abuse
Deficiency Anemia Familial Atrial Fibrillation
Fatty Liver Disease Hepatic Encephalopathy
Hypertension, Essential Major Depressive Disorder
Pancreatitis, Hereditary Protein-Energy Malnutrition
Respiratory Failure Schizophreniform Disorder

Graphical network of the top 20 diseases related to Alcohol Abuse:



Diseases related to Alcohol Abuse

Symptoms & Phenotypes for Alcohol Abuse

UMLS symptoms related to Alcohol Abuse:


hangover from alcohol, hangover from any alcohol or other drugs substance

GenomeRNAi Phenotypes related to Alcohol Abuse according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance GR00251-A-1 9.28 ALDH9A1 CYP2E1
2 Decreased shRNA abundance GR00251-A-2 9.28 ALDH9A1 CYP2E1
3 Decreased shRNA abundance GR00297-A 9.28 ABCB7 AKR1A1 ALDH9A1 CYP2E1 GABRA2
4 Decreased melanin production GR00056-A 9.13 ALDH9A1 SLC17A5 UROD

MGI Mouse Phenotypes related to Alcohol Abuse:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 TF UROD SLC6A4 SLC17A5 ABCB7 DRD3
2 behavior/neurological MP:0005386 10.13 SLC6A4 SLC17A5 DRD2 DRD3 DRD4 ALDH2
3 integument MP:0010771 9.85 SLC6A4 DRD2 ALDH2 ALDH9A1 FAAH BDNF
4 mortality/aging MP:0010768 9.83 SLC6A4 TF UROD SLC17A5 ABCB7 DRD3
5 nervous system MP:0003631 9.4 SLC6A4 SLC17A5 DRD2 ABCB7 DRD3 DRD4

Drugs & Therapeutics for Alcohol Abuse

Drugs for Alcohol Abuse (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 361)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bupropion Approved Phase 4,Phase 2,Phase 1 34911-55-2, 34841-39-9 444
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 64-17-5 702
4
Fluoxetine Approved, Vet_approved Phase 4,Phase 2 54910-89-3 3386
5
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2 77337-76-9 71158
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Clonidine Approved Phase 4 4205-90-7 2803
8 Nefopam Approved, Investigational Phase 4 13669-70-0
9
Ropivacaine Approved Phase 4 84057-95-4 175805 71273
10
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
11
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
12
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
13
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
14
Topiramate Approved Phase 4,Phase 2,Phase 3 97240-79-4 5284627
15
Ondansetron Approved Phase 4,Phase 2,Phase 3,Phase 1 99614-02-5 4595
16
Citalopram Approved Phase 4,Phase 2 59729-33-8 2771
17
Chlorzoxazone Approved Phase 4 95-25-0 2733
18
Methylphenidate Approved, Investigational Phase 4,Phase 1,Early Phase 1 20748-11-2, 113-45-1 4158
19
Varenicline Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 249296-44-4 5310966
20
Dutasteride Approved, Investigational Phase 4 164656-23-9 6918296 152945
21
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 2 68291-97-4 5734
22
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
23
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
24
Haloperidol Approved Phase 4 52-86-8 3559
25
Lorazepam Approved Phase 4,Phase 2 846-49-1 3958
26
Ribavirin Approved Phase 4,Phase 2 36791-04-5 37542
27
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
28
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
29
Disulfiram Approved Phase 4,Phase 2 97-77-8 3117
30
Sertraline Approved Phase 4,Phase 2,Phase 1 79617-96-2 68617
31
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 89594 942
32
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 2 52485-79-7 644073 40400
33
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
34
Methadone Approved Phase 4,Phase 2 76-99-3 4095
35
Naloxone Approved, Vet_approved Phase 4,Phase 3 465-65-6 5284596
36
Gabapentin Approved, Investigational Phase 4,Phase 3,Phase 2 60142-96-3 3446
37
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Phase 2 56-12-2 119
38
Cocaine Approved, Illicit Phase 4,Phase 2,Phase 1 50-36-2 446220 5760
39
Oxytocin Approved, Vet_approved Phase 4,Phase 2,Phase 1 50-56-6 53477758 439302
40
Olanzapine Approved, Investigational Phase 4,Phase 2 132539-06-1 4585
41
Isoniazid Approved, Investigational Phase 4 54-85-3 3767
42
Clozapine Approved Phase 4 5786-21-0 2818
43
Heroin Approved, Illicit, Investigational Phase 4 561-27-3 5462328
44 tannic acid Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
45
Choline Approved, Nutraceutical Phase 4,Phase 1,Phase 2 62-49-7 305
46
Glutamic Acid Approved, Nutraceutical Phase 4,Phase 2 56-86-0 33032
47
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
48
Pyridoxal Approved, Nutraceutical Phase 4 66-72-8 1050
49
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
50 Antidepressive Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 724)

# Name Status NCT ID Phase Drugs
1 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4 fluoxetine;bupropion
2 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
3 Epidural Analgesia for Pancreatitis (Epipan Study) Unknown status NCT02126332 Phase 4
4 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4 Lamotrigine;Placebo
5 Atomoxetine Treatment of Adults With ADHD and Comorbid Alcohol Abuse Completed NCT00190957 Phase 4 Atomoxetine;placebo
6 Quetiapine in Patients With Bipolar and Alcohol Abuse/Dependence Completed NCT00223249 Phase 4 Quetiapine
7 STAR*D Alcohol: Treatment of Depression Concurrent With Alcohol Abuse Completed NCT00369746 Phase 4 citalopram
8 Naltrexone Treatment of Alcohol Abuse in Schizophrenia Completed NCT00145847 Phase 4 Naltrexone or Placebo
9 Acamprosate Added to Escitalopram and Behavioral Treatment for Comorbid Depression and Alcoholism Completed NCT00452543 Phase 4 acamprosate;escitalopram;Placebo
10 Placebo-Controlled Cross Over Trial of Chlorzoxazone Intake Completed NCT01342341 Phase 4 Parafon Forte
11 Adolescent Family-Based Alcohol Prevention Completed NCT00858065 Phase 4
12 Efficacy and Tolerability of Topiramate in Treatment of Bipolar Mania and Alcohol Use in Adolescents and Young Adults Completed NCT00550394 Phase 4 quetiapine and placebo;Quetiapine and Topiramate
13 Treatment of Patients With Alcoholism and Attention Deficit Disorder Completed NCT00261872 Phase 4 Methylphenidate
14 Bupropion as a Smoking Cessation Aid in Alcoholics Completed NCT00044434 Phase 4 bupropion (Wellbutrin)
15 Varenicline in Drug Treatment Completed NCT01286584 Phase 4 varenicline;placebo
16 Dutasteride for the Reduction of Alcohol Use in Male Drinkers Completed NCT01262287 Phase 4 Dutasteride;Placebo
17 Zonisamide vs. Placebo in the Treatment of Alcohol Dependence Completed NCT00595556 Phase 4 zonisamide;Placebo
18 Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy Completed NCT01087736 Phase 4 Topiramate
19 Citicoline for Alcohol Dependence Completed NCT02074735 Phase 4 Placebo;Citicoline
20 AID-trial Assertive Intervention After Deliberate Self-harm Completed NCT00700089 Phase 4
21 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
22 Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism Completed NCT00246441 Phase 4 Paroxetine;Placebo
23 A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room Completed NCT00457366 Phase 4 Quetiapine;Cocktail (Haloperidol, Lorazepam, Cogentin)
24 Prospective Anti-Hepatitis C Virus (Anti-HCV) Trial of Peg-Interferon and Ribavirin in Subjects of First Nations, Metis and Caucasian Ethnicity Completed NCT00957866 Phase 4 Pegylated Interferons (Peg-IFN) and Ribavirin
25 The Effects of a Parental Intervention on Electronic Media Exposure and Sleep Patterns in Adolescents Completed NCT02365025 Phase 4
26 Paroxetine - Controlled Release in the Treatment of Irritable Bowel Syndrome (IBS) Completed NCT00610909 Phase 4 Paroxetine CR;Placebo
27 Letigen® and Cardiovascular Morbidity Completed NCT00692666 Phase 4
28 Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder Completed NCT00156715 Phase 4 Quetiapine
29 Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder Completed NCT00130923 Phase 4 Risperidone Long Acting;oral risperidone
30 Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine) Completed NCT00006204 Phase 4 naltrexone (Revia);fluoxetine (Prozac)
31 Naltrexone, Craving, and Drinking Completed NCT00006203 Phase 4 naltrexone (Revia)
32 Naltrexone Treatment of Alcohol Dependence Completed NCT00000452 Phase 4 naltrexone (Revia)
33 Behavior and Naltrexone Treatment for Alcoholics Completed NCT00000449 Phase 4 naltrexone (Revia)
34 Use of Naltrexone in a Clinical Setting Completed NCT00000445 Phase 4 naltrexone (Revia)
35 Drug Therapy for Alcohol Detoxification Completed NCT00000441 Phase 4 lorazepam (Ativan);carbamazepine (Tegretol)
36 Adjunctive Topiramate for Treatment of Alcohol Dependence in Patients With Bipolar Disorder Completed NCT00572117 Phase 4 Topiramate
37 The Whole Day First Grade Program Completed NCT00257088 Phase 4
38 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4 Drug;Placebo
39 Pharmacogenetic Response to Naltrexone For Alcohol Dependence Completed NCT00831272 Phase 4 naltrexone;Placebo
40 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4 disulfiram plus lorazepam
41 Naltrexone for Heavy Drinking in Young Adults Completed NCT00568958 Phase 4 naltrexone;placebo naltrexone
42 Targeted Naltrexone for Problem Drinkers Completed NCT00369408 Phase 4 Naltrexone;placebo
43 Sertraline Pharmacotherapy for Alcoholism Subtypes Completed NCT00368550 Phase 4 Sertraline;Placebo
44 The Effects of Topiramate on Alcohol Use in Alcohol Dependent Subjects Completed NCT00329407 Phase 4 Topiramate (Topamax)
45 Treatment of Alcohol Withdrawal in Hospital Patients Completed NCT00249366 Phase 4 Lorazepam (drug);Lorazepam
46 Combination Nicotine Replacement for Alcoholic Smokers Completed NCT00064844 Phase 4
47 Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone) Completed NCT00006489 Phase 4 Naltrexone;Placebo
48 Post-Treatment Effects of Naltrexone Completed NCT00006449 Phase 4 naltrexone (Revia)
49 Behavioral Counseling for Alcohol Dependent Smokers (Nicotine Patch) Completed NCT00004551 Phase 4 nicotine replacement patch
50 Behavioral Therapy Plus Naltrexone for Alcoholism Completed NCT00000456 Phase 4 naltrexone (Revia)

Search NIH Clinical Center for Alcohol Abuse

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: alcoholism

Genetic Tests for Alcohol Abuse

Anatomical Context for Alcohol Abuse

MalaCards organs/tissues related to Alcohol Abuse:

38
Brain, Liver, Testes, Lung, Bone, Heart, Breast

Publications for Alcohol Abuse

Articles related to Alcohol Abuse:

(show top 50) (show all 715)
# Title Authors Year
1
Everyday memory problems in alcohol abuse and dependence: Frequency, patterns and patient-proxy agreement. ( 29360054 )
2018
2
Do general practitioners record alcohol abuse in the electronic medical records? A comparison of survey and medical record data. ( 29301406 )
2018
3
Effect of Chronic Alcohol Abuse on Anabolic and Catabolic Signaling Pathways in Human Skeletal Muscle. ( 29044624 )
2018
4
The Alcohol-Abuse Drug Disulfiram Targets NPL4 to Exert Antitumor Effects. ( 29247017 )
2018
5
Development and validation of a Partial Least Squares-Discriminant Analysis (PLS-DA) model based on the determination of ethyl glucuronide (EtG) and fatty acid ethyl esters (FAEEs) in hair for the diagnosis of chronic alcohol abuse. ( 29174052 )
2018
6
Cancer: Anticancer effects of alcohol abuse drug. ( 29386611 )
2018
7
Effects of Alcohol Abuse on Proliferating Cells, Stem/Progenitor Cells, and Immature Neurons in the Adult Human Hippocampus. ( 29052615 )
2018
8
Hypokalemia associated with pseudo-Cushing's syndrome and magnesium deficiency induced by chronic alcohol abuse. ( 29450857 )
2018
9
Theoretical Foundations of Appeals Used in Alcohol-Abuse and Drunk-Driving Public Service Announcements in the United States, 1995-2010. ( 28511551 )
2017
10
Mood disorder, anxiety, and suicide risk among subjects with alcohol abuse and/or dependence: a population-based study. ( 28658442 )
2017
11
Association of Physical Activity with Alcohol Abuse and Dependence in a Nationally-Representative U.S. Sample. ( 28704120 )
2017
12
Favorable effects of motivational interviewing and support in a patient with schizophrenia and alcohol abuse. ( 29264040 )
2017
13
Burden of Alcohol Abuse or Dependence Among Long-Term Opioid Users with Chronic Noncancer Pain. ( 28650247 )
2017
14
CERVICAL TRANSFORMATION IN ALCOHOL ABUSE PATIENTS. ( 29099694 )
2017
15
The association between alcohol abuse and neuroendocrine system dysregulation: Race differences in a National sample. ( 28751021 )
2017
16
The Power of Negative Mood in Predicting Posttraumatic Stress Disorder and Alcohol Abuse Comorbidity. ( 29022727 )
2017
17
Chronic Alcohol Abuse Leads to Low Bone Mass with No General Loss of Bone Structure or Bone Mechanical Strength(). ( 27864963 )
2017
18
Chronic alcohol abuse in men alters bone mechanical properties by affecting both tissue mechanical properties and microarchitectural parameters. ( 28410916 )
2017
19
The effects of seasonal affective disorder and alcohol abuse on sleep and snoring functions in a population-based study in Finland. ( 28901656 )
2017
20
More Likely to Dropout, but What if They Don't? Partner Violence Offenders With Alcohol Abuse Problems Completing Batterer Intervention Programs. ( 29294698 )
2017
21
The Role of the Melanocortin System in Drug and Alcohol Abuse. ( 29056149 )
2017
22
Zinc deficiency as a mediator of toxic effects of alcohol abuse. ( 29177978 )
2017
23
College Students' Responses to Emotional Anti-Alcohol Abuse Media Messages: Should We Scare or Amuse Them? ( 28705030 )
2017
24
Alcohol Abuse is Associated with Enhanced Pulmonary and Systemic Xanthine Oxidoreductase Activity. ( 28839105 )
2017
25
Alcohol Abuse and Cardiac Disease. ( 28057245 )
2017
26
Patterns of Alcohol Abuse, Depression, and Intimate Partner Violence Among Township Mothers in South Africa Over 5 Years. ( 29027039 )
2017
27
Adverse Childhood Experiences (ACEs) and Alcohol Abuse among South Carolina Adults. ( 29185846 )
2017
28
Experiences of severe childhood maltreatment, depression, anxiety and alcohol abuse among adults in Finland. ( 28481912 )
2017
29
The effects of residential dual diagnosis treatment on alcohol abuse. ( 28868159 )
2017
30
Correction: Experiences of severe childhood maltreatment, depression, anxiety and alcohol abuse among adults in Finland. ( 28640921 )
2017
31
Genetic divergence in the transcriptional engram of chronic alcohol abuse: A laser-capture RNA-seq study of the mouse mesocorticolimbic system. ( 27894806 )
2017
32
Re-evaluation of the reward comparison hypothesis for alcohol abuse. ( 28606627 )
2017
33
Contextual Factors Related to Alcohol Abuse Among Intimate Partner Violence Offenders. ( 27759488 )
2017
34
Dissecting the Role of Disturbed ER-Golgi Trafficking in Antivirals and Alcohol Abuse-Induced Pathogenesis of Liver Disorders. ( 29399658 )
2017
35
Drinking Status Between Ages 50 and 55 for Men From the San Diego Prospective Study Who Developed DSM-IV Alcohol Abuse or Dependence in Prior Follow-Ups. ( 28728633 )
2017
36
Elevated inflammation in association with alcohol abuse among Blacks but not Whites: results from the MIDUS biomarker study. ( 29230616 )
2017
37
Traumatic Brain Injuries during Development: Implications for Alcohol Abuse. ( 28775682 )
2017
38
Sporadic Porphyria Cutanea Tarda Induced by Alcohol Abuse. ( 28776562 )
2017
39
Solid-phase extraction of the alcohol abuse biomarker phosphatidylethanol using newly synthesized polymeric sorbent materials containing quaternary heterocyclic groups. ( 28890270 )
2017
40
Seasonal affective disorder and alcohol abuse disorder in a population-based study. ( 28364591 )
2017
41
Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. ( 29211715 )
2017
42
Testing the effectiveness of a transdiagnostic treatment approach in reducing violence and alcohol abuse among families in Zambia: study protocol of the Violence and Alcohol Treatment (VATU) trial. ( 29230314 )
2017
43
Gender Differences in Suicidal Behaviors: Mediation Role of Psychological Distress Between Alcohol Abuse/Dependence and Suicidal Behaviors. ( 28805555 )
2017
44
Lights! Camera! Action Projects! Engaging Psychopharmacology Students in Service-based Action Projects Focusing on Student Alcohol Abuse. ( 27385923 )
2016
45
Maternal drug or alcohol abuse is associated with decreased head size from mid-pregnancy to childhood. ( 27037638 )
2016
46
Alcohol abuse recovery through the lens of Manitoban First Nations and Aboriginal women: A qualitative study. ( 27115828 )
2016
47
Correlates of depression in self-neglecting older adults: A cross-sectional study examining the role of alcohol abuse and pain in increasing vulnerability. ( 26716386 )
2016
48
Chronic alcohol abuse. ( 27903033 )
2016
49
Alcohol abuse and smoking alter inflammatory mediator production by pulmonary and systemic immune cells. ( 26747782 )
2016
50
Couples living with and around alcohol abuse: A study of a farmworker community in the Cape Winelands, South Africa. ( 27043369 )
2016

Variations for Alcohol Abuse

Expression for Alcohol Abuse

LifeMap Discovery
Genes differentially expressed in tissues of Alcohol Abuse patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 ADAMTS18 ADAM metallopeptidase with thrombospondin type 1 motif, 18 Brain - 3.66 0.005
Search GEO for disease gene expression data for Alcohol Abuse.

Pathways for Alcohol Abuse

Pathways related to Alcohol Abuse according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.91 AKR1A1 ALDH2 ALDH9A1 UROD
3
Show member pathways
11.67 DRD2 DRD3 DRD4
4 11.59 CNR1 DRD3 DRD4
5
Show member pathways
11.55 DRD2 DRD3 DRD4
6
Show member pathways
11.17 AKR1A1 ALDH2 ALDH9A1 CYP2E1
7 10.92 AKR1A1 ALDH2 ALDH9A1
8
Show member pathways
10.5 ALDH2 CYP2E1

GO Terms for Alcohol Abuse

Cellular components related to Alcohol Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endocytic vesicle GO:0030139 8.8 DRD2 DRD3 TF

Biological processes related to Alcohol Abuse according to GeneCards Suite gene sharing:

(show all 31)
# Name GO ID Score Top Affiliating Genes
1 response to drug GO:0042493 9.95 CYP2E1 DRD2 DRD3 SLC6A4
2 response to ethanol GO:0045471 9.81 CNR1 CYP2E1 DRD2 DRD3
3 social behavior GO:0035176 9.77 DRD3 DRD4 SLC6A4
4 response to cocaine GO:0042220 9.75 CNR1 DRD2 DRD3
5 negative regulation of adenylate cyclase activity GO:0007194 9.74 DRD2 DRD3 DRD4
6 negative regulation of blood pressure GO:0045776 9.67 CNR1 DRD2 DRD3
7 synaptic transmission, dopaminergic GO:0001963 9.65 DRD2 DRD3
8 response to morphine GO:0043278 9.65 CNR1 DRD2 DRD3
9 behavioral response to ethanol GO:0048149 9.64 DRD2 DRD4
10 neurotransmitter biosynthetic process GO:0042136 9.64 ALDH9A1 SLC6A4
11 negative regulation of voltage-gated calcium channel activity GO:1901386 9.63 DRD2 DRD4
12 prepulse inhibition GO:0060134 9.63 DRD2 DRD3
13 response to amphetamine GO:0001975 9.63 DRD2 DRD3 DRD4
14 positive regulation of renal sodium excretion GO:0035815 9.62 DRD2 DRD3
15 regulation of synaptic transmission, GABAergic GO:0032228 9.62 CNR1 DRD2
16 G-protein coupled receptor internalization GO:0002031 9.61 DRD2 DRD3
17 cellular aldehyde metabolic process GO:0006081 9.61 AKR1A1 ALDH9A1
18 regulation of cAMP metabolic process GO:0030814 9.6 DRD2 DRD3
19 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.58 DRD2 DRD3
20 arachidonic acid secretion GO:0050482 9.58 DRD2 DRD3 DRD4
21 negative regulation of dopamine secretion GO:0033602 9.56 CNR1 DRD2
22 positive regulation of dopamine uptake involved in synaptic transmission GO:0051586 9.55 DRD2 DRD4
23 negative regulation of dopamine receptor signaling pathway GO:0060160 9.54 DRD2 DRD3
24 behavioral response to cocaine GO:0048148 9.54 DRD2 DRD3 DRD4
25 acid secretion GO:0046717 9.52 DRD2 DRD3
26 dopamine receptor signaling pathway GO:0007212 9.5 DRD2 DRD3 DRD4
27 regulation of locomotion involved in locomotory behavior GO:0090325 9.43 DRD2 DRD3
28 negative regulation of protein secretion GO:0050709 9.43 DRD2 DRD3 DRD4
29 dopamine metabolic process GO:0042417 9.33 DRD2 DRD3 DRD4
30 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.13 DRD2 DRD3 DRD4
31 response to histamine GO:0034776 8.8 DRD2 DRD3 DRD4

Molecular functions related to Alcohol Abuse according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 drug binding GO:0008144 9.56 CNR1 DRD2 DRD3 DRD4
2 dopamine binding GO:0035240 9.33 DRD2 DRD3 DRD4
3 aldehyde dehydrogenase (NAD) activity GO:0004029 9.32 ALDH2 ALDH9A1
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 9.13 DRD2 DRD3 DRD4
5 dopamine neurotransmitter receptor activity GO:0004952 8.8 DRD2 DRD3 DRD4

Sources for Alcohol Abuse

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....